Nothing Special   »   [go: up one dir, main page]

HUE063388T2 - Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása - Google Patents

Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása

Info

Publication number
HUE063388T2
HUE063388T2 HUE17736459A HUE17736459A HUE063388T2 HU E063388 T2 HUE063388 T2 HU E063388T2 HU E17736459 A HUE17736459 A HU E17736459A HU E17736459 A HUE17736459 A HU E17736459A HU E063388 T2 HUE063388 T2 HU E063388T2
Authority
HU
Hungary
Prior art keywords
nucleotidase
ecto
modulators
Prior art date
Application number
HUE17736459A
Other languages
English (en)
Inventor
Laurent Debien
Juan Jaen
Jaroslaw Kalisiak
Kenneth V Lawson
Manmohan Reddy Leleti
Erick Lindsey
Dillon Harding Miles
Eric Newcomb
Jay Patrick Powers
Brandon Reid Rosen
Ehesan Ui Sharif
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of HUE063388T2 publication Critical patent/HUE063388T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
HUE17736459A 2016-01-08 2017-01-06 Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása HUE063388T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662276564P 2016-01-08 2016-01-08
US201662324077P 2016-04-18 2016-04-18

Publications (1)

Publication Number Publication Date
HUE063388T2 true HUE063388T2 (hu) 2024-01-28

Family

ID=59274491

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17736459A HUE063388T2 (hu) 2016-01-08 2017-01-06 Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása

Country Status (28)

Country Link
US (5) US10239912B2 (hu)
EP (2) EP3399984B1 (hu)
JP (3) JP6920344B2 (hu)
KR (1) KR20180100638A (hu)
CN (2) CN114395005A (hu)
AU (2) AU2017206061B2 (hu)
BR (1) BR112018013827B1 (hu)
CA (2) CA3009196C (hu)
CL (1) CL2018001845A1 (hu)
DK (1) DK3399984T3 (hu)
EA (1) EA038565B1 (hu)
ES (1) ES2963759T3 (hu)
FI (1) FI3399984T3 (hu)
HR (1) HRP20231155T1 (hu)
HU (1) HUE063388T2 (hu)
IL (1) IL260260B2 (hu)
LT (1) LT3399984T (hu)
MX (2) MX2018008350A (hu)
PH (1) PH12018501361A1 (hu)
PL (1) PL3399984T3 (hu)
PT (1) PT3399984T (hu)
SA (1) SA518391985B1 (hu)
SG (1) SG11201805506YA (hu)
SI (1) SI3399984T1 (hu)
TW (2) TWI744274B (hu)
UA (1) UA124529C2 (hu)
WO (1) WO2017120508A1 (hu)
ZA (2) ZA201804350B (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018013827B1 (pt) 2016-01-08 2024-02-20 Arcus Biosciences, Inc Moduladores de 5-nucleotidase, ecto, composição farmacêutica, combinação, kit e uso dos mesmos
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
US11267845B2 (en) 2016-11-18 2022-03-08 Arcus Biosciences, Inc. Inhibitors of CD73-mediated immunosuppression
PT3551627T (pt) 2016-12-08 2022-04-06 H Hoffnabb La Roche Ag Novos derivados de éter isoxazolílico enquanto moduladores alostéricos positivos de gaba a α5
US10570167B2 (en) * 2016-12-22 2020-02-25 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
AU2018346447A1 (en) 2017-10-06 2020-03-19 Innate Pharma Restoration of T cell activity via the CD39/CD73 axis
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019129059A1 (zh) * 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
TWI702954B (zh) * 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
AU2019231781A1 (en) * 2018-03-09 2020-10-22 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
KR20210018255A (ko) * 2018-04-30 2021-02-17 오릭 파마슈티칼스, 인크. Cd73 억제제
DK3807316T3 (da) 2018-06-18 2024-07-29 Innate Pharma Sammensætninger og fremgangsmåder til behandling af cancer
WO2020037275A1 (en) * 2018-08-17 2020-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors
EP3843742A4 (en) 2018-08-28 2022-04-20 Jiangsu Hengrui Medicine Co., Ltd. CD73 INHIBITORS AND THEIR THERAPEUTIC USES
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
CN110885352B (zh) * 2018-09-11 2023-02-24 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
AU2019339924C1 (en) * 2018-09-11 2022-07-14 Risen (Suzhou) Pharma Tech Co. Ltd. CD73 inhibitors and pharmaceutical uses thereof
US11819512B2 (en) 2018-12-13 2023-11-21 Arcus Biosciences, Inc. Solid forms of a CD73 inhibitor and the use thereof
KR20210114963A (ko) 2019-01-11 2021-09-24 오메로스 코포레이션 암을 치료하기 위한 방법 및 조성물
CN112955444B (zh) * 2019-01-22 2023-12-12 江苏恒瑞医药股份有限公司 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用
JP2022524559A (ja) * 2019-03-12 2022-05-06 アーカス バイオサイエンシーズ，インコーポレーテッド がん遺伝子によって促進されるがんの処置
WO2020205538A1 (en) * 2019-03-29 2020-10-08 Eternity Bioscience Inc. Cd73 inhibitors and therapeutic uses thereof
CN113874397A (zh) * 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
EP3952874A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE ARGININE METHYLTRANSFERASE 5 PROTEIN INHIBITORS
WO2020210938A1 (en) * 2019-04-15 2020-10-22 Bioardis Llc Quinazoline derivatives as cd73 inhibitors
WO2020210970A1 (en) * 2019-04-16 2020-10-22 Bioardis Llc Imidazotriazine derivatives as cd73 inhibitors
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
CN114502174A (zh) * 2019-06-14 2022-05-13 南方研究院 2,4,7取代的-7-脱氮-2′-脱氧-2′-氟阿拉伯糖基核苷和核苷酸前药及其用途
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
KR20220038453A (ko) * 2019-08-29 2022-03-28 일라이 릴리 앤드 캄파니 Cd73 억제제의 결정질 형태
EP4051688A4 (en) 2019-10-30 2024-03-06 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
TW202131932A (zh) * 2019-11-05 2021-09-01 美商博奥阿迪斯有限公司 作為cd73抑制劑的化合物
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
AR122493A1 (es) 2020-06-02 2022-09-14 Arcus Biosciences Inc Anticuerpos anti-tigit
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
WO2021257643A1 (en) * 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
WO2022007677A1 (zh) * 2020-07-07 2022-01-13 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CN116348118A (zh) * 2020-09-08 2023-06-27 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CN114437038A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
CN114437039A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 Cd73抑制剂及其应用
EP4251633A4 (en) * 2020-11-25 2024-09-25 Risen Suzhou Pharma Tech Co Ltd CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF
CN114539340B (zh) * 2020-11-25 2024-06-07 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
EP4273153A4 (en) * 2020-12-29 2024-05-08 Zhejiang Vimgreen Pharmaceuticals, Ltd ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF
WO2022237747A1 (zh) 2021-05-11 2022-11-17 四川海思科制药有限公司 小分子cd73拮抗剂及其用途
EP4341261A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl compounds
WO2022246179A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl inhibitor compounds
WO2023061319A1 (zh) * 2021-10-11 2023-04-20 南京明德新药研发有限公司 三并环杂环衍生物
EP4422643A1 (en) 2021-10-26 2024-09-04 Southern Research Institute Development of novel clofarabine analogs for cancer therapy
IL312348A (en) 2021-10-29 2024-06-01 Arcus Biosciences Inc HIF-2ALPHA inhibitors and methods of using it
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024059142A1 (en) 2022-09-14 2024-03-21 Arcus Biosciences, Inc. Dispersions of etrumadenant
US20240140980A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2024076872A1 (en) * 2022-10-03 2024-04-11 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en) 2022-10-20 2024-04-25 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569650A (en) * 1993-06-11 1996-10-29 Sloan-Kettering Institute For Cancer Research C-nucleoside isosters of analogs thereof and pharmaceutical compositions
KR100560182B1 (ko) * 1996-10-09 2006-03-13 파마셋 인코포레이티드 비스포스포네이트 화합물
CA2429352A1 (en) * 2000-12-15 2002-06-20 Lieven Stuyver Antiviral agents for treatment of flaviviridae infections
WO2012032513A1 (en) * 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
EP3116542A2 (en) * 2014-03-12 2017-01-18 Yeda Research and Development Co., Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
JP6657182B2 (ja) 2014-04-25 2020-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2017029601A1 (en) 2015-08-17 2017-02-23 Lupin Limited Heteroaryl derivatives as parp inhibitors
UY37062A (es) 2016-01-08 2017-08-31 Syngenta Participations Ag Derivados de aryl oxadiazol fungicidas
US9938254B2 (en) 2016-01-08 2018-04-10 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
BR112018013827B1 (pt) 2016-01-08 2024-02-20 Arcus Biosciences, Inc Moduladores de 5-nucleotidase, ecto, composição farmacêutica, combinação, kit e uso dos mesmos
AU2019231781A1 (en) 2018-03-09 2020-10-22 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
US11819512B2 (en) 2018-12-13 2023-11-21 Arcus Biosciences, Inc. Solid forms of a CD73 inhibitor and the use thereof
WO2021257643A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof

Also Published As

Publication number Publication date
US10239912B2 (en) 2019-03-26
EA201891583A1 (ru) 2019-01-31
CN108697719A (zh) 2018-10-23
JP2021167351A (ja) 2021-10-21
EP3399984A1 (en) 2018-11-14
EA038565B1 (ru) 2021-09-15
US11001603B2 (en) 2021-05-11
BR112018013827B1 (pt) 2024-02-20
TW201805006A (zh) 2018-02-16
CN114395005A (zh) 2022-04-26
FI3399984T3 (fi) 2023-11-10
US20170267710A1 (en) 2017-09-21
PT3399984T (pt) 2023-11-21
US20240352057A1 (en) 2024-10-24
JP2023129628A (ja) 2023-09-14
AU2017206061A1 (en) 2018-07-19
LT3399984T (lt) 2023-11-10
TW202227095A (zh) 2022-07-16
US20210371449A1 (en) 2021-12-02
US10981944B2 (en) 2021-04-20
AU2017206061B2 (en) 2022-12-15
AU2023201288A1 (en) 2023-04-06
JP7322104B2 (ja) 2023-08-07
CA3009196A1 (en) 2017-07-13
UA124529C2 (uk) 2021-10-05
EP3399984B1 (en) 2023-09-06
KR20180100638A (ko) 2018-09-11
US11667662B2 (en) 2023-06-06
JP6920344B2 (ja) 2021-08-18
PL3399984T3 (pl) 2024-02-19
WO2017120508A1 (en) 2017-07-13
EP4306525A2 (en) 2024-01-17
SG11201805506YA (en) 2018-07-30
DK3399984T3 (da) 2023-11-13
SI3399984T1 (sl) 2024-01-31
CN108697719B (zh) 2024-03-19
IL260260B2 (en) 2024-01-01
ZA202209472B (en) 2023-06-28
JP2019501223A (ja) 2019-01-17
EP4306525A3 (en) 2024-03-20
MX2022006322A (es) 2022-06-22
ZA201804350B (en) 2023-11-29
IL260260A (en) 2018-07-31
EP3399984A4 (en) 2020-01-01
CA3009196C (en) 2022-05-31
CL2018001845A1 (es) 2018-12-07
TWI744274B (zh) 2021-11-01
US20190309010A1 (en) 2019-10-10
SA518391985B1 (ar) 2022-12-19
ES2963759T3 (es) 2024-04-01
MX2018008350A (es) 2019-05-30
HRP20231155T1 (hr) 2024-01-05
WO2017120508A8 (en) 2018-07-05
BR112018013827A2 (pt) 2018-12-11
US20210002322A1 (en) 2021-01-07
CA3151595A1 (en) 2017-07-13
AU2017206061A8 (en) 2018-07-26
IL260260B1 (en) 2023-09-01
PH12018501361A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
ZA202209472B (en) Modulators of 5'-nucleotidase, ecto and the use thereof
EP3601367A4 (en) CHEMERICAL MOLECULES AND ASSOCIATED USES
EP3720502A4 (en) CYTOBIOLOGICAL PRODUCTS AND THEIR THERAPEUTIC USES
EP3529279A4 (en) CD133 BINDERS AND USE THEREOF
PT3225112T (pt) Dispersão de fotossensibilizador e utilização da mesma
EP3453401A4 (en) INTERLEUKIN COMBINATION AND THEIR USE
RS64556B1 (sr) Novi polipeptidi i njihova upotreba u medicini
EP3512517A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF ANXIETY AND DEPRESSION
ZA201907150B (en) Substituted n-(-1,3,4-oxadiazole-2-yl)aryl carboxamides and the use thereof as herbicides
EP3537895A4 (en) NOVEL MOGROSIDES AND USES THEREOF
EP3724188C0 (en) PROGRANULIN MODULATORS AND METHODS OF USE THEREOF
IL267184A (en) Phenylamidines and the use thereof as fungicides
GB2552063B (en) Medical scope accessory, medical scopes comprising the accessory, and use thereof
IL272164A (en) 3-acyl-benzamides and their use as herbicides
IL267258A (en) Phenoxyphenylamidines and the use thereof as fungicides
PL3327201T3 (pl) Pojemnik i jego zastosowanie
EP3703805A4 (en) MAGNETICALLY ASSISTED ADMINISTRATION IN AND THROUGH THE SKIN
PT3664800T (pt) Formulações terapêuticas que compreendem inibidor da cox-2 e utilizações das mesmas
GB201616087D0 (en) Algae comprising therapeutic and/or nutritional agents
AU2016901401A0 (en) Webfish and the term "webfishing"
GB201716745D0 (en) New formulations and uses thereof
EP3454684A4 (en) ONE-WAY FACE MASK AND METHOD FOR PRODUCING THEREOF
GB201715609D0 (en) Postie's friend
AU2016902114A0 (en) "Chimeric molecules and uses thereof"
EP3489253A4 (en) NEW PEPTIDE AND ITS USE